Gynecomastia: Diagnostic and therapy;Gynäkomastie: Diagnostik und therapie

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 49, 2008, Pages 2567-2571

  Jacobeit, Jens W ^a   Kliesch, S ^b  

^a ENDOKRINOLOGIKUM HAMBURG   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Anabolic steroids; Antiandrogene treatment prostate cancer; Gynecomastia; Klinefelter's syndrome; Male breast cancer; Puberty; Tamoxifen

Indexed keywords

AMIODARONE; ANABOLIC AGENT; ANASTROZOLE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; BRCA2 PROTEIN; CAPTOPRIL; CHORIONIC GONADOTROPIN BETA SUBUNIT; CLOMIFENE CITRATE; DANAZOL; DIGITOXIN; DILTIAZEM; ENALAPRIL; ESTROGEN; FLUTAMIDE; METHYLDOPA; NIFEDIPINE; NILUTAMIDE; RESERPINE; SPIRONOLACTONE; TAMOXIFEN; TESTOLACTONE; VERAPAMIL;

ANTIANDROGEN THERAPY; ARTICLE; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG CONTRAINDICATION; DRUG INDICATION; ECHOMAMMOGRAPHY; ENDOCRINE DISEASE; ESTROGEN RELEASE; GENE MUTATION; GENETIC RISK; GYNECOMASTIA; HUMAN; KLINEFELTER SYNDROME; LOCAL THERAPY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PROPHYLAXIS; PROSTATE CARCINOMA; PUBERTY; RISK FACTOR; TESTIS TUMOR; THORAX RADIOGRAPHY;

ADULT; ANABOLIC AGENTS; ANDROGEN ANTAGONISTS; BREAST NEOPLASMS, MALE; CARDIOVASCULAR AGENTS; DIAGNOSIS, DIFFERENTIAL; GYNECOMASTIA; HUMANS; KLINEFELTER SYNDROME; LEYDIG CELL TUMOR; LIPECTOMY; MALE; MASTECTOMY, SUBCUTANEOUS; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROSTATIC NEOPLASMS; PUBERTY; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 57649115470     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1105855     Document Type: Article

References (31)

1. Autorino R, Perdona S et al. Gynecomastia in patients with prostate cancer: update on treatment options, rostate Cancer Prostatic Dis 2006; 9: 109-114
2. Boccardo F, Rubagotti A et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005; 23: 808-815
3. Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357: 1229-1237
4. Carvajal A, Macias D et al. Gynecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System. Drug Saf 2007; 30: 527-531
5. Chalazonitis AN, Theodossiades GD et al. Bilateral gynecomastia with microcalcifications in an HIV infected hemophilia A patient after HAART. Jbr-Btr 2006; 89: 328-
6. Cuculi F, Suter A et al. Spironolactone-induced gynecomastia. CMAJ 2007; 176: 620-
7. DDG, Lv.d.S.A.d.D.D.G. AWMF-Leitlinien 2004; Register Nr. 013/039
8. de la Torre A, Ramada Benlloch F, Sánchez Ballester F et al. Management of male sterility in patients taking anabolic steroids Arch Esp Urol 2005; 58: 241-244
9. Di Lorenzo G, Perdona S et al. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol 2005; 174: 2197-2203
10. Ewertz M, Holmberg L et al. Risk factors for male breast cancer - a case-control study from Scandinavia. Acta Oncol 2001; 40: 467-471
11. Fradet Y, Egerdie B et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol 2007; 52: 106-114
12. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005; 10: 471-479
13. Henley DV, Lipson N et al. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 2007; 356: 479-485
14. Hochberg Z. Practical Algorithms in Pediatric Endocrinology. Freiburg: Karger, 2007
15. Karagiannis A, Tziomalos K et al. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrol Dial Transplant 2007; 22: 293-
16. Khan HN, Blamey RW. Endocrine treatment of physiological gynaecomastia. BMJ 2003; 327: 301-302
17. Khan HN, Rampaul R et al. Management of physiological gynaecomastia with tamoxifen. Breast 2004; 13: 61-65
18. Kliesch S, Behre HM et al. Rationale Therapie der Hitzewallungen unter Hormonentzugsbehandlung bei Patienten mit fortgeschrittenem Prostatakarzinom. Dtsch Med Wochenschr 1997; 122: 940-945
19. Lazala C, Saenger P. Pubertal gynecomastia. J Pediatr Endocrinol Metab 2002; 15: 553-560
20. Narula HS, Carlson HE. Gynecomastia. Endocrinol Metab Clin North Am 2007; 36: 497-519
21. Nuttall MC, Harris JP et al. The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain. BJU Int 2007; 99: 243-244
22. Perdona S, Autorino R et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005; 6: 295-300
23. Prisant LM, Chin E. Gynecomastia and hypertension. J Clin Hypertens (Greenwich) 2005; 7: 245-248
24. Rose LI, Underwood RH et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977; 87: 398-403
25. Smith RA, Saslow D et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003; 53: 141-169
26. Tashkandi M, Al-Qattan MM et al. The surgical management of high-grade gynecomastia. Ann Plast Surg 2004; 53: 17-20
27. Than RS, Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertil Steril 2003; 79:
28. Thonnessen D, Wenz F. Radiotherapeutic prophylaxis of gynecomastia. J Clin Oncol 2005; 23: 5845-
29. UpToDate Prevention and treatment of gynecomastia, UpToDate 2007 95 Sawyer Road Waltham, MA 02453 United States
30. Yavuz M, Kesiktas E et al. Lighted retractor-assisted transaxillary approach in gynecomastia correction. Ann Plast Surg 2006; 57: 370-373
31. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J Clin Endocrinol Metab 2004; 89: 6208-6217